<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Treatment of Alzheimer disease</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Treatment of Alzheimer disease</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Treatment of Alzheimer disease</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Daniel Press, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Stephanie S Buss, MD</a></dd><dt><span> </span>Section Editors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Steven T DeKosky, MD, FAAN, FACP, FANA</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Kenneth E Schmader, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Janet L Wilterdink, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Sep 30, 2021.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H485519119"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Alzheimer disease (AD) is a neurodegenerative disorder of uncertain cause and pathogenesis that primarily affects older adults and is the most common cause of dementia. The most essential and often earliest clinical manifestation of AD is selective memory impairment, although there are exceptions. While treatments are available that can ameliorate some symptoms of the illness, there is no cure currently available, and the disease inevitably progresses in all patients.</p><p>This topic discusses the treatment of AD. Other aspects of AD are discussed separately:</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/5071.html" rel="external">"Clinical features and diagnosis of Alzheimer disease"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/16575.html" rel="external">"Epidemiology, pathology, and pathogenesis of Alzheimer disease"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/16195.html" rel="external">"Genetics of Alzheimer disease"</a>.)</p><p></p><p class="headingAnchor" id="H2817512211"><span class="h1">PATIENT REFERRAL</span><span class="headingEndMark"> — </span>Timing of referral to a specialist depends upon the comfort and knowledge base of the primary care provider in managing dementia and on the availability of specialty clinics where additional resources are available, such as social workers and neuropsychologists. Factors that are important in considering patient referral are when there is uncertainty about the diagnosis of an early dementia (eg, when difficulty arises distinguishing dementia from normal aging, depression, or encephalopathy), when a non-Alzheimer dementia is likely (early and severe behavioral changes, language problems, hallucinations, or parkinsonism), when there is a young onset (&lt;65 years old), and when there is a strong family history.</p><p class="headingAnchor" id="H2"><span class="h1">CHOLINESTERASE INHIBITORS</span><span class="headingEndMark"> — </span>Patients with AD have reduced cerebral content of choline acetyltransferase, which leads to a decrease in acetylcholine synthesis and impaired cortical cholinergic function. Cholinesterase inhibitors (<a class="drug drug_general" data-topicid="9383" href="/d/drug information/9383.html" rel="external">donepezil</a>, <a class="drug drug_general" data-topicid="9529" href="/d/drug information/9529.html" rel="external">rivastigmine</a>, and <a class="drug drug_general" data-topicid="8739" href="/d/drug information/8739.html" rel="external">galantamine</a>) increase cholinergic transmission by inhibiting cholinesterase at the synaptic cleft and provide modest symptomatic benefit in patients with AD. </p><p>The majority of patients with newly diagnosed AD should be offered a trial of a cholinesterase inhibitor for symptomatic treatment of cognition and global functioning. As discussed below, the degree of expected benefit is modest, and therapy should not be continued indefinitely in patients who do not appear to be benefiting or who have significant side effects. There is no convincing evidence that cholinesterase inhibitors are neuroprotective or have the ability to alter the underlying disease trajectory. (See  <a class="medical medical_review" href="/d/html/5072.html" rel="external">"Cholinesterase inhibitors in the treatment of dementia", section on 'Duration of therapy'</a>.)</p><p>Cholinesterase inhibitors have been studied in patients with varying severities of dementia. Although eligibility criteria are not uniform across all trials and cutoffs are variably defined, dementia severity can generally be categorized by Mini-Mental State Examination (MMSE), Montreal Cognitive Assessment (MoCA), or clinical dementia rating (CDR) scores  (<a class="graphic graphic_table graphicRef53706" href="/d/graphic/53706.html" rel="external">table 1</a>) as follows:</p><p class="bulletIndent1"><span class="glyph">●</span>Mild dementia – MMSE 19 to 26; MoCA 12 to 16; CDR 1</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Moderate dementia – MMSE 10 to 18; MoCA 4 to 11; CDR 2</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Severe dementia – MMSE &lt;10; MoCA &lt;4; CDR 3</p><p></p><p class="headingAnchor" id="H3053641237"><span class="h2">Mild to moderate dementia</span><span class="headingEndMark"> — </span>For patients with newly diagnosed mild to moderate AD dementia, we suggest a trial of a cholinesterase inhibitor. The choice of agent, dosing, administration, and side effects are described separately  (<a class="graphic graphic_table graphicRef63284" href="/d/graphic/63284.html" rel="external">table 2</a>). (See  <a class="medical medical_review" href="/d/html/5072.html" rel="external">"Cholinesterase inhibitors in the treatment of dementia"</a>.)</p><p>The average benefit of cholinesterase inhibitors in patients with mild to moderate dementia (eg, MMSE 10 to 26; MoCA 4 to 16; CDR 1 or 2) is a small improvement in cognition, neuropsychiatric symptoms, and activities of daily living (ADLs) [<a href="#rid1">1-8</a>].</p><p>The degree of benefit is summarized by a meta-analysis of 13 randomized trials of <a class="drug drug_general" data-topicid="9383" href="/d/drug information/9383.html" rel="external">donepezil</a>, <a class="drug drug_general" data-topicid="8739" href="/d/drug information/8739.html" rel="external">galantamine</a>, or <a class="drug drug_general" data-topicid="9529" href="/d/drug information/9529.html" rel="external">rivastigmine</a> versus placebo in more than 3000 patients with AD (mostly mild to moderate disease severity) [<a href="#rid6">6</a>]. When assessed at 6 to 12 months, cholinesterase inhibitors led to modest improvements on the 70-point Alzheimer Disease Assessment Scale-Cognitive Subscale (ADAS-Cog; mean difference 2.7 points, 95% CI 2.3-3.0) and MMSE (mean difference 1.37 points, 95% CI 1.13-1.61) as well as global impression by caregivers and ADLs. One analysis estimated that these effects would be similar to preventing a two-months-per-year decline in a typical patient with AD [<a href="#rid1">1</a>]; another concluded that for every 12 patients treated, one would benefit by achieving minimal improvement or better and one would develop a treatment-related adverse effect [<a href="#rid9">9</a>].</p><p>Whether these drugs significantly improve long-term outcomes, such as the need for nursing home admission or maintaining critical ADLs, remains in doubt, and the evidence is conflicting [<a href="#rid1">1,10-14</a>]. The AD2000 study, one of few nonindustry-sponsored trials of a cholinesterase inhibitor versus placebo with long-term follow-up, found no significant benefit of <a class="drug drug_general" data-topicid="9383" href="/d/drug information/9383.html" rel="external">donepezil</a> compared with placebo for the two primary endpoints: entry to institutional care and progression of disability [<a href="#rid10">10</a>].</p><p>Additional evidence suggests that the response to cholinesterase inhibitors may be quite variable, with as much as 30 to 50 percent of patients showing no observable benefit [<a href="#rid15">15,16</a>], while a smaller proportion (up to 20 percent) may show a greater than average response (≥7 point ADAS-Cog improvement) [<a href="#rid17">17,18</a>]. These findings reinforce the importance of making individualized decisions for each patient based on clinical response and side effects.</p><p class="headingAnchor" id="H3198023417"><span class="h2">Advanced disease</span><span class="headingEndMark"> — </span>The relative effects of cholinesterase inhibitors appear to be similar for patients with more severe dementia (eg, MMSE &lt;10; MoCA &lt;4; CDR 3) at the time of diagnosis, but fewer studies have been performed and the absolute effects may be less clinically important than those seen in patients with mild to moderate dementia.</p><p>As in earlier-stage disease, small benefits on some but not all cognitive and functional outcomes have been noted in short-term trials of either <a class="drug drug_general" data-topicid="9383" href="/d/drug information/9383.html" rel="external">donepezil</a> or <a class="drug drug_general" data-topicid="8739" href="/d/drug information/8739.html" rel="external">galantamine</a> in previously untreated community-dwelling adults and nursing home residents with moderate to advanced dementia [<a href="#rid19">19-23</a>].</p><p>Decisions on long-term use depend on the patient's functional response to treatment and long-term goals of care and should be made in consultation with caregivers and family [<a href="#rid24">24</a>]. (See  <a class="medical medical_review" href="/d/html/5072.html" rel="external">"Cholinesterase inhibitors in the treatment of dementia", section on 'Follow-up and monitoring'</a>.)</p><p class="headingAnchor" id="H3"><span class="h1">MEMANTINE</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="10131" href="/d/drug information/10131.html" rel="external">Memantine</a> is an N-methyl-D-aspartate (NMDA) receptor antagonist. The mechanism of action of memantine is distinct from those of the cholinergic agents; it is proposed to be neuroprotective. Glutamate is the principal excitatory amino acid neurotransmitter in cortical and hippocampal neurons [<a href="#rid25">25</a>]. One of the receptors activated by glutamate is the NMDA receptor, which is involved in learning and memory [<a href="#rid26">26</a>]. Excessive NMDA stimulation can be induced by ischemia and lead to excitotoxicity, suggesting that agents that block pathologic stimulation of NMDA receptors may protect against further damage in patients with vascular dementia (VaD) [<a href="#rid27">27</a>]. In addition, the physiologic function of the remaining neurons could be restored, resulting in symptomatic improvement [<a href="#rid28">28</a>].</p><p><a class="drug drug_general" data-topicid="10131" href="/d/drug information/10131.html" rel="external">Memantine</a> does not appear to have significant side effects. A 2008 systemic review concluded that memantine has been shown to improve cognition and global assessment of dementia, but with small effects that are not of clear clinical significance; improvement in quality of life and other domains are suggested but not proven [<a href="#rid2">2</a>]. As a result, treatment decisions should be individualized and include considerations of drug tolerability and cost [<a href="#rid24">24</a>].</p><p class="headingAnchor" id="H619734897"><span class="h2">Moderate to severe Alzheimer disease</span><span class="headingEndMark"> — </span>We suggest the use of <a class="drug drug_general" data-topicid="10131" href="/d/drug information/10131.html" rel="external">memantine</a> in combination with a cholinesterase inhibitor in patients with advanced AD. A combination capsule of <a class="drug drug_general" data-topicid="98777" href="/d/drug information/98777.html" rel="external">donepezil-memantine</a> in two different strengths is available. </p><p><a class="drug drug_general" data-topicid="10131" href="/d/drug information/10131.html" rel="external">Memantine</a> appears to have modest benefits in patients with moderate to severe AD: </p><p class="bulletIndent1"><span class="glyph">●</span>A 28-week randomized trial in 252 patients with AD with Mini-Mental State Examination (MMSE) scores of 3 to 14 (mean approximately 8) at study entry found that <a class="drug drug_general" data-topicid="10131" href="/d/drug information/10131.html" rel="external">memantine</a> significantly reduced deterioration on multiple scales of clinical efficacy [<a href="#rid29">29</a>]. Adverse event rates with memantine were similar to placebo, and more patients taking placebo than memantine discontinued the study medication. An open-label extension to this study demonstrated benefits for patients previously taking placebo in all efficacy measures relative to their previous rate of decline, and also confirmed the favorable adverse event profile seen in the double-blind study [<a href="#rid30">30</a>]. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>A clinical trial of 295 patients with moderate to severe AD who were already taking <a class="drug drug_general" data-topicid="9383" href="/d/drug information/9383.html" rel="external">donepezil</a> compared the efficacy of four treatment strategies: no therapy (donepezil discontinued), donepezil continued alone, donepezil continued with <a class="drug drug_general" data-topicid="10131" href="/d/drug information/10131.html" rel="external">memantine</a> added, and memantine therapy alone [<a href="#rid13">13</a>]. After one year, patients assigned to receive memantine therapy had a higher score on the standardized MMSE and a lower score on the Bristol Activities of Daily Living Scale (both implying benefit) compared with those not receiving memantine; however, the average differences in scores (1.2 and 1.5 points, respectively) did not meet the prespecified threshold considered to be clinically important. The trial was stopped early due to slow recruitment. With long-term follow-up, memantine had no effect on the rate of nursing home placement over a four-year period after randomization [<a href="#rid14">14</a>].</p><p></p><p>The combination of <a class="drug drug_general" data-topicid="10131" href="/d/drug information/10131.html" rel="external">memantine</a> and a cholinesterase inhibitor leads to modest improvements in cognition and global outcomes in patients with advanced disease [<a href="#rid31">31</a>]. The largest trials demonstrating the efficacy of combination therapy include the following:</p><p class="bulletIndent1"><span class="glyph">●</span>A 24-week trial studied the effects of either <a class="drug drug_general" data-topicid="10131" href="/d/drug information/10131.html" rel="external">memantine</a> or placebo in addition to <a class="drug drug_general" data-topicid="9383" href="/d/drug information/9383.html" rel="external">donepezil</a> in 322 patients with moderate to severe AD [<a href="#rid32">32</a>]. MMSE scores ranged from 5 to 14 (mean approximately 10) at study entry. Treatment with memantine plus donepezil resulted in significantly better outcomes than placebo plus donepezil on measures of cognition, activities of daily living (ADLs), global outcome, and behavior. Significantly more patients taking placebo than memantine discontinued the trial, and the rate of discontinuation due to adverse events was lower in the memantine-treated group than in the placebo group.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>A second 24-week randomized trial compared <a class="drug drug_general" data-topicid="10131" href="/d/drug information/10131.html" rel="external">memantine</a> with placebo in 433 patients with mild to moderate AD who were on stable doses of a cholinesterase inhibitor (either <a class="drug drug_general" data-topicid="9383" href="/d/drug information/9383.html" rel="external">donepezil</a>, <a class="drug drug_general" data-topicid="9529" href="/d/drug information/9529.html" rel="external">rivastigmine</a>, or <a class="drug drug_general" data-topicid="8739" href="/d/drug information/8739.html" rel="external">galantamine</a>) [<a href="#rid33">33</a>]. There was no difference in outcome measures between the treatment groups.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>A clinical trial of 295 patients with moderate to severe AD who were already taking <a class="drug drug_general" data-topicid="9383" href="/d/drug information/9383.html" rel="external">donepezil</a> compared the efficacy at one year of four treatment strategies: no therapy (donepezil discontinued), donepezil continued alone, donepezil continued with <a class="drug drug_general" data-topicid="10131" href="/d/drug information/10131.html" rel="external">memantine</a> added, and memantine therapy alone as discussed above [<a href="#rid13">13</a>]. No significant benefits of the combination of <a class="drug drug_general" data-topicid="98777" href="/d/drug information/98777.html" rel="external">donepezil-memantine</a> over donepezil alone were noted; however, this study was stopped early due to slow recruitment.</p><p></p><p class="headingAnchor" id="H723102619"><span class="h2">Other patient groups</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Mild AD</strong> – There is little, if any, evidence that patients with milder AD benefit from <a class="drug drug_general" data-topicid="10131" href="/d/drug information/10131.html" rel="external">memantine</a>. A systematic review reported the results of pooled data from three unpublished studies of memantine in mild to moderate AD [<a href="#rid34">34</a>]. Intention-to-treat analysis indicated a very small but statistically significant beneficial effect for memantine at six months on cognition (&lt;1 point on the 70-point Alzheimer Disease Assessment Scale-Cognitive Subscale [ADAS-Cog]) but no effect on behavior or ADLs. Another study analyzed data on 431 patients with mild AD (MMSE 20 to 23) from three trials and found no substantial benefit with memantine [<a href="#rid35">35</a>]. No benefit was seen in patients assigned to memantine in the Department of Veterans Affairs (VA) Cooperative Studies Program discussed below [<a href="#rid36">36</a>]. (See <a class="local">'Vitamin E'</a> below.) </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Vascular or mixed dementia</strong> – <a class="drug drug_general" data-topicid="10131" href="/d/drug information/10131.html" rel="external">Memantine</a> has shown some evidence of efficacy in patients with VaD. (See  <a class="medical medical_review" href="/d/html/5086.html" rel="external">"Treatment of vascular cognitive impairment and dementia"</a>.) </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Down syndrome</strong> – The prevalence of AD in older patients (&gt;40 years) with Down syndrome is very high, suggesting that treatments effective in the general population with AD might be of benefit in these patients as well. (See  <a class="medical medical_review" href="/d/html/2917.html" rel="external">"Down syndrome: Clinical features and diagnosis", section on 'Dementia/Alzheimer disease'</a>.)</p><p></p><p class="bulletIndent1">However, we do not advise use of <a class="drug drug_general" data-topicid="10131" href="/d/drug information/10131.html" rel="external">memantine</a> in patients with Down syndrome. A randomized trial of memantine in 173 patients &gt;40 years in age with Down syndrome found no benefit to memantine therapy after 52 weeks on treatment [<a href="#rid37">37</a>]. A low baseline prevalence of dementia (35 percent) at onset of treatment may have contributed to the negative results. </p><p></p><p class="headingAnchor" id="H3572909010"><span class="h2">Dosing</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="10131" href="/d/drug information/10131.html" rel="external">Memantine</a> is initiated 5 mg once daily; the dose can be increased by 5 mg weekly to a maximum tolerated dose of 20 mg per day, usually in two divided doses. An extended-release form for once-daily administration is available.</p><p>When medication is discontinued, a tapering schedule with a similar timeline should be followed. </p><p class="headingAnchor" id="H4170273666"><span class="h2">Adverse effects</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="10131" href="/d/drug information/10131.html" rel="external">Memantine</a> also appears to have fewer side effects than the cholinergic agents [<a href="#rid34">34</a>]. Dizziness is the most common side effect associated with memantine. Confusion and hallucinations are reported to occur at a low frequency, but we have noticed that memantine use seems to increase agitation and delusional behaviors in some patients with AD. Others have reported that worsening of delusions and hallucinations is particularly problematic in patients who have dementia with Lewy bodies (DLB) [<a href="#rid38">38</a>].</p><p class="headingAnchor" id="H2549013834"><span class="h1">ADUCANUMAB</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="131816" href="/d/drug information/131816.html" rel="external">Aducanumab</a> is a recombinant monoclonal antibody directed against amyloid beta. The US Food and Drug Administration (FDA) has approved aducanumab for the treatment of mild AD using the accelerated approval pathway, based on the positive clinical results of one of the two pivotal phase III trials (the results in the other were negative) and aducanumab's effect on a surrogate endpoint of reducing amyloid beta plaques in the brain [<a href="#rid39">39</a>].</p><p>The approval of this medication has led to significant controversy given that the FDA scientific advisory panel had previously recommended against approval of <a class="drug drug_general" data-topicid="131816" href="/d/drug information/131816.html" rel="external">aducanumab</a>, and since the surrogate endpoint of reducing amyloid beta plaques is not yet established as predicting clinical benefit [<a href="#rid40">40-47</a>]. Postapproval trials are required to verify the clinical benefit. As the first new therapy for AD since 2003, there is a great deal of excitement in the community, but this must be tempered by the lack of clarity in the clinical trials, the risk of adverse effects, and the monitoring requirements. </p><p class="headingAnchor" id="H574011930"><span class="h2">Patient selection</span><span class="headingEndMark"> — </span>To date, <a class="drug drug_general" data-topicid="131816" href="/d/drug information/131816.html" rel="external">aducanumab</a> has been administered primarily in research settings. Its approval by the FDA was controversial, and it is likely that clinical practice will vary initially and evolve over time. </p><p>At present, there is uncertainty about whether patients with AD benefit clinically from <a class="drug drug_general" data-topicid="131816" href="/d/drug information/131816.html" rel="external">aducanumab</a>. Thus, we suggest against the routine use of aducanumab for patients with AD. However, some patients with mild AD and their physicians may reasonably choose treatment with aducanumab despite the unknown benefit and known risks of treatment [<a href="#rid48">48</a>]. In accordance with proposed appropriate use criteria  (<a class="graphic graphic_table graphicRef132726" href="/d/graphic/132726.html" rel="external">table 3</a>) [<a href="#rid49">49</a>], aducanumab should only be considered for selected patients with mild cognitive impairment (MCI) due to AD or mild AD itself. Patient selection is based upon neurologic and physical examination and dementia staging, which should be completed by an experienced clinician who performs cognitive testing along with appropriate laboratory testing and magnetic resonance imaging (MRI) of the brain.</p><p>The use of <a class="drug drug_general" data-topicid="131816" href="/d/drug information/131816.html" rel="external">aducanumab</a> should be limited to the following patients [<a href="#rid49">49</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Mild cognitive impairment or mild dementia</strong> – Cognitive decline should be mild, and testing cutoffs such as Mini-Mental State Examination (MMSE) ≥21, Montreal Cognitive Assessment (MoCA) ≥17, or clinical dementia rating (CDR) 0.5 to 1 can be used. Formal neuropsychological testing can be considered for quantification of deficits and changes over time.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Documented amyloid pathology</strong> – Clinicians should limit use of <a class="drug drug_general" data-topicid="131816" href="/d/drug information/131816.html" rel="external">aducanumab</a> to those patients proven to be amyloid positive (by amyloid positron emission tomography [PET] scan or lumbar puncture), as was required in the clinical trials that evaluated the drug. (See  <a class="medical medical_review" href="/d/html/5071.html" rel="external">"Clinical features and diagnosis of Alzheimer disease", section on 'Neuroimaging'</a> and  <a class="medical medical_review" href="/d/html/5071.html" rel="external">"Clinical features and diagnosis of Alzheimer disease", section on 'Role of biomarkers'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>No contraindications</strong> – Patients with cognitive decline attributed to non-AD pathologies (eg, Lewy body disease, vascular dementia [VaD]) should not be offered <a class="drug drug_general" data-topicid="131816" href="/d/drug information/131816.html" rel="external">aducanumab</a>. At present, experts suggest against treating patients with AD in the setting of Down syndrome until more information is available [<a href="#rid49">49</a>].</p><p></p><p class="bulletIndent1">Patients should not be offered <a class="drug drug_general" data-topicid="131816" href="/d/drug information/131816.html" rel="external">aducanumab</a> if they have a high risk of hemorrhagic side effects. Risk factors include hemorrhagic findings on brain MRI including &gt;4 microhemorrhages, any areas of superficial siderosis, prior macrohemorrhage, and underlying brain lesion or vascular malformation. Other risk factors contraindicating treatment are anticoagulant or antiplatelet use (other than <a class="drug drug_general" data-topicid="8907" href="/d/drug information/8907.html" rel="external">aspirin</a> 81 mg daily), bleeding disorders, or any other condition leading to increased risk of central nervous system (CNS) hemorrhage. </p><p></p><p class="bulletIndent1"><a class="drug drug_general" data-topicid="131816" href="/d/drug information/131816.html" rel="external">Aducanumab</a> should also not be offered to patients with unstable medical conditions, patients with unstable psychiatric conditions, or patients who are pregnant or breastfeeding.</p><p></p><p>As patients with an apolipoprotein E epsilon 4 (<em>APOE</em> ε4) allele have a greater risk of side effects, clinicians should also discuss with patients whether to check <em>APOE</em> allele status prior to initiating treatment (see <a class="local">'Amyloid-related imaging abnormalities (ARIA)'</a> below). For patients undergoing <em>APOE</em> genotyping, genetic counseling should be offered to patients and families prior to testing.</p><p>Clinicians and patients also must be able to adhere to the recommended safety and monitoring guidelines discussed below. (See <a class="local">'Monitoring'</a> below and <a class="local">'Risks'</a> below.) </p><p>In addition, it remains uncertain as to whether public and private payers will cover this treatment. It is also uncertain as to whether studies to confirm the presence of amyloid by PET scan or lumbar puncture will be paid for as well. </p><p>Ultimately, the choice to initiate treatment with <a class="drug drug_general" data-topicid="131816" href="/d/drug information/131816.html" rel="external">aducanumab</a> will be an individual one, based on discussion with patients and caregivers that includes both what is known and what is uncertain in regard to benefits, risks, burdens, and costs of therapy. </p><p class="headingAnchor" id="H2096588672"><span class="h2">Dosing and administration</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="131816" href="/d/drug information/131816.html" rel="external">Aducanumab</a> is administered by intravenous (IV) infusion every four weeks, typically in an infusion center. </p><p>A recent (within one year) brain MRI study is required prior to initiating treatment; additional MRIs are required during dose escalation. (See <a class="local">'Monitoring'</a> below.)</p><p class="bulletIndent1"><span class="glyph">●</span>Doses 1 and 2 (weeks 0 and 4) – 1 mg/kg IV over one hour</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Doses 3 and 4 (weeks 8 and 16) – 3 mg/kg IV over one hour</p><p></p><p>A brain MRI is required prior to initiating a fifth dose. (See <a class="local">'Monitoring'</a> below.)</p><p class="bulletIndent1"><span class="glyph">●</span>Doses 5 and 6 (weeks 24 and 32) – 6 mg/kg IV over one hour</p><p></p><p>A brain MRI is required prior to initiating a seventh dose. (See <a class="local">'Monitoring'</a> below.)</p><p class="bulletIndent1"><span class="glyph">●</span>Dose 7 and beyond (week 36 and on) – 10 mg/kg IV over one hour</p><p></p><p>An optional brain MRI could be considered prior to the tenth dose (after three doses of 10 mg <a class="drug drug_general" data-topicid="131816" href="/d/drug information/131816.html" rel="external">aducanumab</a>) for additional monitoring; this should be considered in <em>APOE</em> ε4 carriers [<a href="#rid49">49</a>].</p><p>A brain MRI is required prior to initiating the twelfth dose (week 44). (See <a class="local">'Monitoring'</a> below.)</p><p>If a patient misses three or more doses and the patient and clinical team decide to reinitiate treatment, titration should be restarted at a dose one step lower than the previous dose administered.</p><p>There is no clear guidance regarding duration of treatment with <a class="drug drug_general" data-topicid="131816" href="/d/drug information/131816.html" rel="external">aducanumab</a>. We would not continue after the patient has progressed to moderate dementia. Future guidance may suggest that treatment be stopped once amyloid PET scan is read as negative.</p><p class="headingAnchor" id="H1355547715"><span class="h2">Amyloid-related imaging abnormalities (ARIA)</span></p><p class="headingAnchor" id="H1859080781"><span class="h3">Clinical and neuroimaging features</span><span class="headingEndMark"> — </span>ARIA was reported in approximately 40 percent of patients treated with the highest dose of <a class="drug drug_general" data-topicid="131816" href="/d/drug information/131816.html" rel="external">aducanumab</a> in clinical trials [<a href="#rid50">50</a>]. The risk of ARIA is greater in patients with an <em>APOE</em> ε4 allele. ARIA can occur at any time during treatment but is most common within the first eight doses and/or when dose escalation is occurring.</p><p>ARIA can take the form of edema (ARIA-E) and/or microhemorrhage (ARIA-H). </p><p class="bulletIndent1"><span class="glyph">●</span>ARIA-E is characterized by focal vasogenic edema with fluid-attenuated inversion recovery (FLAIR) hyperintensity; it is thought to have a similar pathophysiology to reversible posterior leukoencephalopathy syndrome (RPLS) [<a href="#rid51">51</a>]. Most patients (70 percent) with ARIA-E are asymptomatic, but others have fatigue, headache, confusion, dizziness, falls, vision change, or nausea. ARIA-E is graded as mild, moderate, or severe  (<a class="graphic graphic_table graphicRef132725" href="/d/graphic/132725.html" rel="external">table 4</a>).</p><p></p><p class="bulletIndent1">In most patients (88 percent), ARIA-E resolves over time without long-term side effects; however, some patients experience a recurrence.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>ARIA-H usually manifests as microhemorrhage and/or superficial siderosis [<a href="#rid51">51</a>]. Macrohemorrhage (hemorrhagic stroke) occurred very infrequently in the clinical trials. ARIA-H often, but not always, occurs concurrently with ARIA-E in the affected brain region. Microhemorrhage will continue to show up on follow-up MRI even after stability.</p><p></p><p class="headingAnchor" id="H961457855"><span class="h3">Monitoring</span><span class="headingEndMark"> — </span>Treatment-related adverse effects (cerebral edema and/or hemorrhage) mandate ongoing monitoring (see <a class="local">'Risks'</a> below). The monitoring recommendations made here align with proposed appropriate use criteria that mimic the procedures used in the clinical trials; these are somewhat different from the FDA label prescribing instructions [<a href="#rid49">49,50</a>].</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Clinical assessments</strong> – During the titration phase, patients should be monitored for clinical symptoms suggestive of a treatment-related adverse effect (eg, headache, confusion, focal neurologic signs including vision disturbance). Serial monitoring with cognitive tests should be administered by the clinical team with each dose administration.</p><p></p><p class="bulletIndent1">In addition, because the presenting symptoms of ARIA may be subtle, and because patients may not be able to report their own symptoms, we recommend that patients are monitored for clinical change by a designated family member or friend for the duration of <a class="drug drug_general" data-topicid="131816" href="/d/drug information/131816.html" rel="external">aducanumab</a> therapy. If this is not possible, remote cognitive assessments administered by the treatment team could alternatively be used to monitor cognitive status.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>MRI monitoring</strong> – A brain MRI is required prior to initiating therapy as well as prior to the fifth, seventh, and twelfth doses to assess for possible adverse effects, especially ARIA. This guidance is somewhat different from the FDA labeling but is recommended by experts and mirrors procedures used in the clinical trials [<a href="#rid49">49</a>].</p><p></p><p class="bulletIndent1">In addition, a brain MRI should be performed for any symptoms suggestive of ARIA (eg, headache, confusion, focal neurologic signs).</p><p></p><p class="bulletIndent1">Brain MRI sequences should include FLAIR, T2*, gradient echo (GRE) or susceptibility-weighted images (SWI), and diffusion-weighted images (DWI). All follow-up brain scans should occur on the same scanner with the same sequences to allow for comparability between the scans.</p><p></p><p class="bulletIndent1">MRIs must be read by an experienced clinician familiar with the detection and reporting of ARIA. ARIA is assessed as mild, moderate, or severe  (<a class="graphic graphic_table graphicRef132725" href="/d/graphic/132725.html" rel="external">table 4</a>). </p><p></p><p class="headingAnchor" id="H2607600684"><span class="h3">Management</span><span class="headingEndMark"> — </span>If a brain MRI shows ARIA, the patient should be evaluated clinically. </p><p class="bulletIndent1"><span class="glyph">●</span><strong>Asymptomatic patients with mild MRI findings</strong> – Patients who are asymptomatic and who have mild MRI changes  (<a class="graphic graphic_table graphicRef132725" href="/d/graphic/132725.html" rel="external">table 4</a>) may be able to continue <a class="drug drug_general" data-topicid="131816" href="/d/drug information/131816.html" rel="external">aducanumab</a> with close clinical monitoring and monthly MRI scans [<a href="#rid49">49</a>]. However, the aducanumab dose should not be increased until ARIA-E resolves even if the patient is asymptomatic. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Symptomatic patients or moderate to severe MRI findings</strong> – <a class="drug drug_general" data-topicid="131816" href="/d/drug information/131816.html" rel="external">Aducanumab</a> should be held for moderate or severe ARIA  (<a class="graphic graphic_table graphicRef132725" href="/d/graphic/132725.html" rel="external">table 4</a>) and/or symptomatic ARIA of any severity [<a href="#rid49">49</a>].</p><p></p><p class="bulletIndent1">Monthly follow-up MRI scans are required to determine whether <a class="drug drug_general" data-topicid="131816" href="/d/drug information/131816.html" rel="external">aducanumab</a> can be restarted in the future after resolution of ARIA-E and documented stability of any hemorrhages [<a href="#rid49">49</a>]. </p><p></p><p class="headingAnchor" id="H1703824149"><span class="h2">Efficacy</span><span class="headingEndMark"> — </span>The efficacy of <a class="drug drug_general" data-topicid="131816" href="/d/drug information/131816.html" rel="external">aducanumab</a> has been evaluated in clinical trials [<a href="#rid52">52</a>]. While a robust effect has been consistently demonstrated in regard to reduction in brain amyloid levels, observed benefits on clinical endpoints have been small and inconsistent and therefore uncertain [<a href="#rid53">53</a>].</p><p>In a dose-escalation phase 1b trial of <a class="drug drug_general" data-topicid="131816" href="/d/drug information/131816.html" rel="external">aducanumab</a> in 165 patients with prodromal or mild AD, substantial reduction of amyloid plaques was demonstrated on amyloid PET imaging in a dose- and time-dependent manner [<a href="#rid54">54</a>]. After 12 months, almost half of patients no longer had positive amyloid PET imaging. However, only small and inconsistent clinical effects were observed on clinical rating scales.</p><p>Two subsequent placebo-controlled trials (EMERGE and ENGAGE) studied patients with MCI due to AD or very mild dementia due to AD (MMSE &gt;24, CDR score of 0.5, and positive amyloid PET scan) [<a href="#rid52">52</a>]. Both trials were stopped early after a planned futility analysis, which examined clinical outcomes. Following this decision, analyses were performed that included additional trial data collected subsequent to the termination decision. Both clinical trials observed a substantial reduction in brain amyloid levels as assessed by amyloid PET imaging; however, the FDA data analysis showed no association between reduction in brain amyloid levels and clinical outcomes [<a href="#rid55">55</a>]. </p><p>In one of these trials (EMERGE; 1638 patients), patients treated with high-dose <a class="drug drug_general" data-topicid="131816" href="/d/drug information/131816.html" rel="external">aducanumab</a> had a smaller clinical decline from baseline compared with those treated with placebo, specifically a 22 percent relative reduction in the CDR Sum of Boxes score at week 78. The absolute difference of 0.39 is of uncertain clinical significance [<a href="#rid56">56</a>]. Small but statistically significant benefits were also noted on three other prespecified secondary outcomes.</p><p>In the other trial (ENGAGE; 1647 patients), the CDR Sum of Boxes scores were not different between patient groups, and benefits were not seen on most secondary outcomes [<a href="#rid57">57</a>]. </p><p>The full results of these studies have not been published in peer-reviewed form.</p><p class="headingAnchor" id="H1724796622"><span class="h2">Risks</span><span class="headingEndMark"> — </span>Adverse effects observed with <a class="drug drug_general" data-topicid="131816" href="/d/drug information/131816.html" rel="external">aducanumab</a> include ARIA, which were reported in approximately 40 percent of patients treated with the highest dose of aducanumab in clinical trials, and especially in <em>APOE</em> ε4 carriers [<a href="#rid50">50</a>]. (See <a class="local">'Amyloid-related imaging abnormalities (ARIA)'</a> above.) </p><p>Hypersensitivity, including angioedema and urticaria, was reported in one patient in the clinical trials [<a href="#rid50">50</a>].</p><p>Headache, falls, diarrhea, and confusion were also modestly more frequent in aducanumab- versus placebo-treated patients [<a href="#rid50">50</a>]. Except for diarrhea, these may reflect symptoms of ARIA.</p><p>Up to 0.6 percent of patients in the clinical trials developed <a class="drug drug_general" data-topicid="131816" href="/d/drug information/131816.html" rel="external">aducanumab</a> antibodies; no determination was made as to whether such antibodies are neutralizing [<a href="#rid50">50</a>].</p><p class="headingAnchor" id="H6"><span class="h1">ANTIOXIDANTS</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="10049" href="/d/drug information/10049.html" rel="external">Vitamin E</a> (alpha-tocopherol) and <a class="drug drug_general" data-topicid="9883" href="/d/drug information/9883.html" rel="external">selegiline</a> (a monoamine oxidase inhibitor) have been studied in AD because of their antioxidant properties, and results from randomized trials have been mixed [<a href="#rid58">58</a>]. Overall, the available data suggest that vitamin E at a dose of 2000 international units per day confers a modest benefit in delaying functional progression in patients with mild to moderate AD, with no measurable effect on cognitive performance. We see no advantage for the use of selegiline, which has more side effects and is more costly.</p><p class="headingAnchor" id="H742548"><span class="h2">Vitamin E</span><span class="headingEndMark"> — </span>We feel that <a class="drug drug_general" data-topicid="10049" href="/d/drug information/10049.html" rel="external">vitamin E</a> (1000 international units twice daily) is a reasonable intervention in patients with mild to moderate AD. Although the available data allow only limited confidence that vitamin E is an effective therapy for AD, this is balanced by the excellent safety and tolerability profile of supplementation in both studies and the general lack of very effective therapies for patients with AD. The benefits of vitamin E are likely to be modest.</p><p>A few randomized trials have examined the effects of <a class="drug drug_general" data-topicid="10049" href="/d/drug information/10049.html" rel="external">vitamin E</a> in patients with AD, with somewhat mixed results [<a href="#rid58">58</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>The Alzheimer Disease Cooperative Study (ADCS) trial compared <a class="drug drug_general" data-topicid="10049" href="/d/drug information/10049.html" rel="external">vitamin E</a>, <a class="drug drug_general" data-topicid="9883" href="/d/drug information/9883.html" rel="external">selegiline</a>, the combination, and placebo [<a href="#rid59">59</a>]. The primary outcome in the study was the time to a combined endpoint of death, institutionalization, loss of the ability to perform activities of daily living (ADLs), or progression to severe dementia on a clinical dementia rating (CDR) scale.</p><p></p><p class="bulletIndent1">There was a delayed progression to outcome for patients treated with <a class="drug drug_general" data-topicid="10049" href="/d/drug information/10049.html" rel="external">vitamin E</a> compared with placebo (440 versus 670 days) after statistical adjustment because the placebo group had higher Mini-Mental State Examination (MMSE) scores at baseline [<a href="#rid59">59</a>]. Performance on cognitive tests (including the MMSE and the Alzheimer Disease Assessment Scale-Cognitive Subscale [ADAS-Cog]) was similar between the groups. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The Department of Veterans Affairs (VA) Cooperative Studies Program compared <a class="drug drug_general" data-topicid="10049" href="/d/drug information/10049.html" rel="external">vitamin E</a> (2000 international units per day), <a class="drug drug_general" data-topicid="10131" href="/d/drug information/10131.html" rel="external">memantine</a> (20 mg per day), the combination, and placebo in 613 (mostly male) patients with mild to moderate AD [<a href="#rid36">36</a>]. </p><p></p><p class="bulletIndent1">After mean follow-up of two years, patients treated with <a class="drug drug_general" data-topicid="10049" href="/d/drug information/10049.html" rel="external">vitamin E</a> experienced 3.15 units smaller decline in the ADCS-ADL Inventory compared with those taking placebo (95% CI 0.92-5.39). There was no evidence of a difference between groups on the ADAS-Cog or MMSE.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In a smaller clinical trial of antioxidant therapy in 78 patients with AD, 16 weeks of treatment with 800 international units per day of <a class="drug drug_general" data-topicid="10049" href="/d/drug information/10049.html" rel="external">vitamin E</a> (along with <a class="drug drug_general" data-topicid="9776" href="/d/drug information/9776.html" rel="external">vitamin C</a> and alpha-lipoic acid) was not associated with changes in cerebrospinal fluid biomarkers related to amyloid or tau pathology, but was associated with an accelerated deterioration in MMSE scores relative to either placebo or coenzyme Q-treated patients [<a href="#rid60">60</a>].</p><p></p><p>High-dose <a class="drug drug_general" data-topicid="10049" href="/d/drug information/10049.html" rel="external">vitamin E</a> supplementation has been inconsistently associated with an increase in all-cause mortality and also with heart failure in patients with cardiovascular disease [<a href="#rid61">61</a>]. Such concerns have not been validated in the AD population, however; in the VA study described above, patients assigned to 2000 international units of vitamin E daily had a trend towards lower annual mortality compared with patients assigned to <a class="drug drug_general" data-topicid="10131" href="/d/drug information/10131.html" rel="external">memantine</a>, the combination, or placebo [<a href="#rid36">36</a>]. (See  <a class="medical medical_review" href="/d/html/5368.html" rel="external">"Vitamin intake and disease prevention", section on 'Mortality'</a>.)</p><p>In summary, although both of the larger studies have issues limiting confidence in the conclusion that <a class="drug drug_general" data-topicid="10049" href="/d/drug information/10049.html" rel="external">vitamin E</a> is an effective therapy for AD, this is balanced by the excellent safety and tolerability profile of supplementation in both studies and the general lack of effective therapies for patients with AD. We therefore feel that vitamin E (2000 international units daily) is a reasonable intervention in patients with mild to moderate AD. The benefits of vitamin E are likely to be modest, however, and could be offset by combination therapy with <a class="drug drug_general" data-topicid="10131" href="/d/drug information/10131.html" rel="external">memantine</a>.</p><p>We do not recommend <a class="drug drug_general" data-topicid="10049" href="/d/drug information/10049.html" rel="external">vitamin E</a> for the routine prevention of AD or for the treatment or prevention of other types of dementia. (See  <a class="medical medical_review" href="/d/html/5075.html" rel="external">"Prevention of dementia", section on 'Antioxidant vitamins'</a>.)</p><p class="headingAnchor" id="H742554"><span class="h2">Selegiline</span><span class="headingEndMark"> — </span>We do not use <a class="drug drug_general" data-topicid="9883" href="/d/drug information/9883.html" rel="external">selegiline</a> in patients with AD as the evidence of efficacy is quite limited.</p><p>The ADCS trial compared <a class="drug drug_general" data-topicid="10049" href="/d/drug information/10049.html" rel="external">vitamin E</a>, <a class="drug drug_general" data-topicid="9883" href="/d/drug information/9883.html" rel="external">selegiline</a>, the combination, and placebo and is discussed above [<a href="#rid59">59</a>]. There was a delayed progression to outcome for patients treated with selegiline compared with placebo (655 versus 670 days) after statistical adjustment because the placebo group had higher MMSE scores at baseline. Performance on cognitive tests (including the MMSE and the ADAS-Cog) was similar between the groups. </p><p>In addition to the ADCS trial, a number of smaller studies have also investigated the use of <a class="drug drug_general" data-topicid="9883" href="/d/drug information/9883.html" rel="external">selegiline</a> with varying results. A meta-analysis of 12 trials found that 8 of the studies suggested some beneficial effect of selegiline in the treatment of cognitive benefits and, in three trials, in the treatment of behavior and mood [<a href="#rid62">62</a>]. Analysis of three studies with a longer-than-one-year follow-up reported significant delays in time to the primary outcome (death, institutionalization, loss of ability to perform ADLs, or severe dementia) [<a href="#rid59">59,63,64</a>]. However, the magnitude of the benefits in the meta-analysis was small and largely dependent on the ADCS study [<a href="#rid59">59</a>]. Thus, the clinical importance for the population at large is unclear.</p><p class="headingAnchor" id="H3531746283"><span class="h1">VASCULAR RISK FACTOR MANAGEMENT</span><span class="headingEndMark"> — </span>Identification and treatment of risk factors for stroke, cardiovascular disease, and dementia may represent an important strategy for slowing the progression of cognitive decline [<a href="#rid65">65</a>]. An observational study compared the progression of Mini-Mental State Examination (MMSE) scores in 301 patients with AD (without cerebrovascular disease history) [<a href="#rid66">66</a>]. Patients whose vascular risk factors were treated had a slower decline in MMSE scores compared with those whose vascular risk factors were not treated. Patients with some but not all of their vascular risk factors treated had an intermediate rate of decline. </p><p>However, data are not entirely consistent, and there are potential harms to overly aggressive risk factor management [<a href="#rid67">67</a>]. As an example, one study in 172 patients with dementia or mild cognitive impairment (MCI) found that MMSE scores declined fastest in patients being treated with antihypertensive drugs who had the lowest tertile of daytime systolic blood pressures (≤128 mmHg) [<a href="#rid68">68</a>]. Orthostatic hypotension associated with overly aggressive blood pressure management is also of concern.</p><p>In addition, strong support from randomized controlled clinical trials of vascular risk factor treatment in patients with dementia is lacking. A randomized study of patients with AD found that after two years, progression of white matter lesions on magnetic resonance imaging (MRI) was less in those who were assigned to aggressive risk factor reduction, but clinical progression was not assessed [<a href="#rid69">69</a>]. </p><p>While a pilot clinical trial demonstrated trends toward benefit for <a class="drug drug_general" data-topicid="8949" href="/d/drug information/8949.html" rel="external">atorvastatin</a> in a 63-patient trial of mild to moderate AD [<a href="#rid70">70</a>], a randomized controlled trial of <a class="drug drug_general" data-topicid="9923" href="/d/drug information/9923.html" rel="external">simvastatin</a> (40 mg per day for 18 months) in 406 patients with mild to moderate AD found no evidence of benefit of therapy on the progression of AD symptoms [<a href="#rid71">71</a>]. Similarly, a randomized clinical trial of 640 patients with mild to moderate AD found that 80 mg of atorvastatin per day did not influence cognitive endpoints after 72 weeks of treatment [<a href="#rid72">72</a>].</p><p>These topics as they relate to the incidence and prevention of dementia are discussed separately. (See  <a class="medical medical_review" href="/d/html/5079.html" rel="external">"Risk factors for cognitive decline and dementia"</a> and  <a class="medical medical_review" href="/d/html/5075.html" rel="external">"Prevention of dementia"</a>.)</p><p class="headingAnchor" id="H1212073114"><span class="h1">BEHAVIORAL DISTURBANCE</span><span class="headingEndMark"> — </span>Behavioral disturbances can profoundly affect patients with dementia as well as their families and caregivers. Recognition and treatment of delusions, hallucinations, depression, agitation, aggression, and sleep disturbances are important aspects of the care of patients with dementia. This topic is discussed separately. (See  <a class="medical medical_review" href="/d/html/5082.html" rel="external">"Management of neuropsychiatric symptoms of dementia"</a> and  <a class="medical medical_review" href="/d/html/97863.html" rel="external">"Sleep-wake disturbances and sleep disorders in patients with dementia"</a>.)</p><p class="headingAnchor" id="H12"><span class="h1">NONPHARMACOLOGIC THERAPY AND SUPPORTIVE CARE</span><span class="headingEndMark"> — </span>The role of nutrition, cognitive rehabilitation, exercise programs, and occupational therapy in the management of patients with dementia is discussed separately. (See  <a class="medical medical_review" href="/d/html/5080.html" rel="external">"Management of the patient with dementia"</a>.)</p><p class="headingAnchor" id="H111550774"><span class="h1">SAFETY AND SOCIETAL ISSUES</span><span class="headingEndMark"> — </span>Safety issues in patients with dementia including driving, financial capacity, wandering, and living alone are discussed separately. (See  <a class="medical medical_review" href="/d/html/5080.html" rel="external">"Management of the patient with dementia"</a>.)</p><p class="headingAnchor" id="H2692254283"><span class="h1">ADVANCED DEMENTIA</span><span class="headingEndMark"> — </span>In the terminal stages of dementia, patients and their caregivers are faced with a range of physical and psychosocial needs, and effective palliative care can improve patients' symptoms, lessen caregiver burden, and help ensure that treatment decisions are well informed and weighed in the context of patient and family goals and needs. Aspects of palliative care that are specific to patients with advanced dementia are discussed separately. (See  <a class="medical medical_review" href="/d/html/86250.html" rel="external">"Care of patients with advanced dementia"</a>.) </p><p class="headingAnchor" id="H1506393829"><span class="h1">THERAPIES WITH UNPROVEN BENEFIT</span><span class="headingEndMark"> — </span>A variety of additional therapies have been explored in patients with dementia with largely negative results.</p><p class="headingAnchor" id="H110942098"><span class="h2">Estrogen replacement</span><span class="headingEndMark"> — </span>There is no evidence that initiating estrogen replacement is beneficial in the treatment or prevention of dementia. </p><p>Studies of estrogen and AD in postmenopausal females have focused on two areas: the role of estrogen in preventing the development of dementia and the potential efficacy of estrogen in the treatment of dementia. These investigations are based upon a large body of preclinical evidence that estrogen enhances cerebral blood flow, prevents atrophy of cholinergic neurons, reduces oxidative stress, and modulates the effects of nerve growth factors [<a href="#rid73">73</a>]. However, large randomized trials have now shown that the use of hormone replacement therapy (HRT) with estrogen plus progestin or estrogen alone in females aged 65 and older who are free from dementia may increase the risk of developing dementia [<a href="#rid74">74-76</a>]. (See  <a class="medical medical_review" href="/d/html/7422.html" rel="external">"Estrogen and cognitive function", section on 'Estrogen and dementia'</a>.)</p><p>Until recently, the majority of studies of estrogen therapy for the treatment of AD have been uncontrolled, unblinded, and of short duration [<a href="#rid77">77</a>]. Three randomized controlled trials of estrogen therapy for treatment of AD involving 42, 50, and 120 females had similar results: Treatment with estrogen at varying doses and for a varying duration of time did not improve cognitive or functional outcomes compared with placebo [<a href="#rid78">78-80</a>]. A fourth trial reported different results: In 20 postmenopausal females with AD who were treated with a relatively high dose of 17-beta <a class="drug drug_general" data-topicid="9422" href="/d/drug information/9422.html" rel="external">estradiol</a> by skin patch (0.1 mg/day) or placebo, active treatment was associated with significant improvement in verbal memory, visual memory, and attention [<a href="#rid81">81</a>].</p><p>A meta-analysis found that females who had menopause symptoms had improvements in verbal memory, vigilance, reasoning, and motor speed with estrogen replacement, but no enhancement of other cognitive functions [<a href="#rid82">82</a>]. No benefits were observed in asymptomatic females. (See  <a class="medical medical_review" href="/d/html/7422.html" rel="external">"Estrogen and cognitive function"</a>.)</p><p>Estrogen does not appear to enhance the effects of cholinesterase inhibitors in patients with AD. A study of 117 females that looked at adding HRT (transdermal <a class="drug drug_general" data-topicid="9422" href="/d/drug information/9422.html" rel="external">estradiol</a> and oral <a class="drug drug_general" data-topicid="9817" href="/d/drug information/9817.html" rel="external">progesterone</a>) to treatment with <a class="drug drug_general" data-topicid="9529" href="/d/drug information/9529.html" rel="external">rivastigmine</a> found no additional benefit in the females randomized to receive HRT [<a href="#rid83">83</a>].</p><p>In summary, we see no current evidence for initiating HRT in patients with established dementia, and, given the data on HRT for primary prevention of dementia, HRT may actually be harmful. (See  <a class="medical medical_review" href="/d/html/7422.html" rel="external">"Estrogen and cognitive function"</a>.)</p><p class="headingAnchor" id="H2126658936"><span class="h2">Antiinflammatory drugs</span><span class="headingEndMark"> — </span>A role for the use of antiinflammatory drugs in the treatment and prevention of AD continues to be investigated. Pathophysiologic studies have demonstrated an amyloid-induced inflammatory reaction with microglial activation and cytokine release [<a href="#rid84">84,85</a>]. In addition, some epidemiologic studies have suggested that use of nonsteroidal antiinflammatory drugs (NSAIDs; and other antiinflammatory medications) are associated with a reduced odds ratio for developing AD [<a href="#rid86">86,87</a>]. (See  <a class="medical medical_review" href="/d/html/5075.html" rel="external">"Prevention of dementia", section on 'NSAID therapy'</a>.)</p><p>However, clinical trials do not support this treatment: Except for one small clinical trial of <a class="drug drug_general" data-topicid="8559" href="/d/drug information/8559.html" rel="external">indomethacin</a> [<a href="#rid88">88</a>], randomized trials of antiinflammatory medications including <a class="drug drug_general" data-topicid="9682" href="/d/drug information/9682.html" rel="external">naproxen</a>, <a class="drug drug_general" data-topicid="8541" href="/d/drug information/8541.html" rel="external">hydroxychloroquine</a>, <a class="drug drug_general" data-topicid="9348" href="/d/drug information/9348.html" rel="external">diclofenac</a>, rofecoxib, and <a class="drug drug_general" data-topicid="8907" href="/d/drug information/8907.html" rel="external">aspirin</a> have not found a benefit for these agents in slowing cognitive decline in patients with AD [<a href="#rid89">89-94</a>]. In addition, adverse events have been more common in treated patients compared with controls.</p><p>In particular, long-term use of the cyclooxygenase 2 (COX-2) inhibitor rofecoxib has been associated with an increased risk of cardiovascular events, and this problem may be a drug class effect of COX-2 inhibitors. In addition, a placebo-controlled AD prevention trial comparing <a class="drug drug_general" data-topicid="8847" href="/d/drug information/8847.html" rel="external">celecoxib</a> with <a class="drug drug_general" data-topicid="9682" href="/d/drug information/9682.html" rel="external">naproxen</a> was suspended in December 2004; the suspension was due to the finding of an increased rate of cardiovascular events in patients receiving celecoxib in an unrelated colonic polyp prevention trial; however, it was announced that subjects receiving naproxen sodium had an increased rate of cardiovascular events. These issues are discussed in detail elsewhere. (See  <a class="medical medical_review" href="/d/html/7968.html" rel="external">"NSAIDs: Adverse cardiovascular effects"</a>.)</p><p class="headingAnchor" id="H1957369490"><span class="h2">Ginkgo biloba</span><span class="headingEndMark"> — </span>A systematic review of ginkgo for cognitive impairment and dementia concluded that ginkgo biloba, while safe, has inconsistent and unconvincing evidence of benefit [<a href="#rid95">95</a>]. There have not been subsequent studies that alter this conclusion. We do not advocate use of ginkgo because of questionable efficacy and lack of regulation, including variability in the dosing and contents of herbal extracts [<a href="#rid96">96</a>]. The studies evaluating ginkgo biloba for the prevention and treatment of dementia are discussed separately. (See  <a class="medical medical_review" href="/d/html/1387.html" rel="external">"Clinical use of ginkgo biloba", section on 'Treatment'</a> and  <a class="medical medical_review" href="/d/html/5075.html" rel="external">"Prevention of dementia", section on 'Ginkgo biloba'</a>.)</p><p class="headingAnchor" id="H1396249136"><span class="h2">Dietary supplements</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Vitamin B</strong> – Supplementation with B vitamins, in particular those that are involved in homocysteine metabolism, have been studied in patients with AD in hopes that they may demonstrate efficacy in preventing or slowing the progression of AD. An 18-month randomized trial of high-dose vitamin B-complex supplementation (folate, B6, B12) in 340 patients with mild to moderate AD found no beneficial effect on cognitive measures [<a href="#rid97">97</a>].</p><p></p><p class="bulletIndent1">A discussion of the rationale and clinical utility of vitamin B-complex supplementation in the prevention of AD is discussed separately. (See  <a class="medical medical_review" href="/d/html/5075.html" rel="external">"Prevention of dementia", section on 'Vitamins B6, B12, and folate'</a>.) </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Omega-3 fatty acids </strong>– Observational studies have suggested a possible association between dietary intake of fish and omega-3 fatty acids and a lower risk of dementia. (See  <a class="medical medical_review" href="/d/html/5075.html" rel="external">"Prevention of dementia"</a>.)</p><p></p><p class="bulletIndent1">However, clinical trials have not supported a therapeutic role for omega-3 fatty acid supplementation in the treatment of AD [<a href="#rid98">98,99</a>].</p><p></p><p class="headingAnchor" id="H2250312143"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/d/html/116344.html" rel="external">"Society guideline links: Cognitive impairment and dementia"</a>.)</p><p class="headingAnchor" id="H12046934"><span class="h1">INFORMATION FOR PATIENTS</span><span class="headingEndMark"> — </span>UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5<sup>th</sup> to 6<sup>th</sup> grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10<sup>th</sup> to 12<sup>th</sup> grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.</p><p>Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient info" and the keyword(s) of interest.) </p><p class="bulletIndent1"><span class="glyph">●</span>Basics topics (see  <a class="medical medical_basics" href="/d/html/15523.html" rel="external">"Patient education: Dementia (including Alzheimer disease) (The Basics)"</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Beyond the Basics topics (see  <a class="medical medical_patient" href="/d/html/736.html" rel="external">"Patient education: Dementia (including Alzheimer disease) (Beyond the Basics)"</a>)</p><p></p><p class="headingAnchor" id="H23"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Cholinesterase inhibitors</strong> – For patients with newly diagnosed Alzheimer disease (AD) dementia, we suggest a trial of a cholinesterase inhibitor (<a class="grade" href="https://medilib.ir/uptodate/show/grade_4" rel="external">Grade 2A</a>).</p><p></p><p class="bulletIndent1">Patients with dementia of mild to moderate severity (eg, Mini-Mental State Examination [MMSE] 10 to 26) may be the most likely to derive clinical benefit, which is typically modest and must be balanced with the risk of adverse effects. Decisions should be individualized in patients with very advanced dementia (eg, MMSE &lt;5) at the time of diagnosis.</p><p></p><p class="bulletIndent1">The choice among <a class="drug drug_general" data-topicid="9383" href="/d/drug information/9383.html" rel="external">donepezil</a>, <a class="drug drug_general" data-topicid="8739" href="/d/drug information/8739.html" rel="external">galantamine</a>, and <a class="drug drug_general" data-topicid="9529" href="/d/drug information/9529.html" rel="external">rivastigmine</a> can be based upon ease of use, individual patient tolerance, cost, and clinician and patient preference, as efficacy appears to be similar. Formulations and dosing are provided in the table  (<a class="graphic graphic_table graphicRef63284" href="/d/graphic/63284.html" rel="external">table 2</a>). (See <a class="local">'Cholinesterase inhibitors'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Memantine</strong> – In patients with moderate to advanced dementia (eg, MMSE ≤18), we suggest adding <a class="drug drug_general" data-topicid="10131" href="/d/drug information/10131.html" rel="external">memantine</a> (10 mg twice daily) to a cholinesterase inhibitor, or using memantine alone in patients who do not tolerate or benefit from a cholinesterase inhibitor (<a class="grade" href="https://medilib.ir/uptodate/show/grade_5" rel="external">Grade 2B</a>). (See <a class="local">'Memantine'</a> above.)</p><p></p><p class="bulletIndent1">In patients with severe dementia (MMSE &lt;10), we suggest continuing <a class="drug drug_general" data-topicid="10131" href="/d/drug information/10131.html" rel="external">memantine</a>, given the possibility that memantine may be disease modifying (<a class="grade" href="https://medilib.ir/uptodate/show/grade_6" rel="external">Grade 2C</a>). However, in some patients with advanced dementia, it may make sense to discontinue administration of medications to maximize quality of life and patient comfort. (See <a class="local">'Memantine'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Aducanumab</strong> – <a class="drug drug_general" data-topicid="131816" href="/d/drug information/131816.html" rel="external">Aducanumab</a> is approved by the US Food and Drug Administration (FDA) for the treatment of mild AD. While aducanumab appears highly effective in reducing brain amyloid levels, it is uncertain that patients benefit clinically from treatment. In addition, aducanumab has known risks that require close monitoring with clinical and imaging assessments. (See <a class="local">'Efficacy'</a> above and <a class="local">'Risks'</a> above.)</p><p></p><p class="bulletIndent1">At present, we suggest <strong>against</strong> the routine use of <a class="drug drug_general" data-topicid="131816" href="/d/drug information/131816.html" rel="external">aducanumab</a> for patients with AD (<a class="grade" href="https://medilib.ir/uptodate/show/grade_6" rel="external">Grade 2C</a>). However, some patients with mild AD and their physicians may reasonably choose this treatment because of the potential (but uncertain) benefit and despite the known risks of treatment. Shared decision-making must include discussions regarding both what is known and what is uncertain in regard to benefits, risks, burdens, and costs of therapy. (See <a class="local">'Patient selection'</a> above.) </p><p></p><p class="bulletIndent1">In addition, safety guidelines for administration and monitoring should be followed, and use of <a class="drug drug_general" data-topicid="131816" href="/d/drug information/131816.html" rel="external">aducanumab</a> should not extend beyond the population of patients that were studied in clinical trials. (See <a class="local">'Dosing and administration'</a> above and <a class="local">'Monitoring'</a> above and <a class="local">'Patient selection'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Vitamin E</strong> – It is reasonable to offer treatment with <a class="drug drug_general" data-topicid="10049" href="/d/drug information/10049.html" rel="external">vitamin E</a> (1000 international units twice daily) to patients with mild to moderate AD after discussing risks and benefits. Experts do not consistently use vitamin E in patients with AD. Vitamin E may provide a benefit in regard to slowing progression of disease; however, the benefit is likely to be small, and some studies suggest that there are risks in patients with cardiovascular disease. (See <a class="local">'Vitamin E'</a> above.) </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Behavioral disturbances</strong> – Behavioral disturbances are common in individuals with dementia and may respond to symptomatic treatment. (See  <a class="medical medical_review" href="/d/html/5082.html" rel="external">"Management of neuropsychiatric symptoms of dementia"</a>.)</p><p></p><p class="headingAnchor" id="H2727633031"><span class="h1">ACKNOWLEDGMENT</span><span class="headingEndMark"> — </span>The UpToDate editorial staff acknowledges Michael Alexander, MD, who contributed to an earlier version of this topic review.</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Trinh NH, Hoblyn J, Mohanty S, Yaffe K. Efficacy of cholinesterase inhibitors in the treatment of neuropsychiatric symptoms and functional impairment in Alzheimer disease: a meta-analysis. JAMA 2003; 289:210.</a></li><li><a class="nounderline abstract_t">Raina P, Santaguida P, Ismaila A, et al. Effectiveness of cholinesterase inhibitors and memantine for treating dementia: evidence review for a clinical practice guideline. Ann Intern Med 2008; 148:379.</a></li><li><a class="nounderline abstract_t">Doody RS, Stevens JC, Beck C, et al. Practice parameter: management of dementia (an evidence-based review). Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2001; 56:1154.</a></li><li><a class="nounderline abstract_t">Kaduszkiewicz H, Zimmermann T, Beck-Bornholdt HP, van den Bussche H. Cholinesterase inhibitors for patients with Alzheimer's disease: systematic review of randomised clinical trials. BMJ 2005; 331:321.</a></li><li><a class="nounderline abstract_t">Birks JS, Grimley Evans J. Rivastigmine for Alzheimer's disease. Cochrane Database Syst Rev 2015; :CD001191.</a></li><li><a class="nounderline abstract_t">Birks J. Cholinesterase inhibitors for Alzheimer's disease. Cochrane Database Syst Rev 2006; 2006:CD005593.</a></li><li><a class="nounderline abstract_t">Birks J, Harvey RJ. Donepezil for dementia due to Alzheimer's disease. Cochrane Database Syst Rev 2006; :CD001190.</a></li><li><a class="nounderline abstract_t">Birks J, Craig D. Galantamine for vascular cognitive impairment. Cochrane Database Syst Rev 2006; :CD004746.</a></li><li><a class="nounderline abstract_t">Lanctôt KL, Herrmann N, Yau KK, et al. Efficacy and safety of cholinesterase inhibitors in Alzheimer's disease: a meta-analysis. CMAJ 2003; 169:557.</a></li><li><a class="nounderline abstract_t">Courtney C, Farrell D, Gray R, et al. Long-term donepezil treatment in 565 patients with Alzheimer's disease (AD2000): randomised double-blind trial. Lancet 2004; 363:2105.</a></li><li><a class="nounderline abstract_t">Schneider LS. AD2000: donepezil in Alzheimer's disease. Lancet 2004; 363:2100.</a></li><li><a class="nounderline abstract_t">Lopez OL, Becker JT, Wisniewski S, et al. Cholinesterase inhibitor treatment alters the natural history of Alzheimer's disease. J Neurol Neurosurg Psychiatry 2002; 72:310.</a></li><li><a class="nounderline abstract_t">Howard R, McShane R, Lindesay J, et al. Donepezil and memantine for moderate-to-severe Alzheimer's disease. N Engl J Med 2012; 366:893.</a></li><li><a class="nounderline abstract_t">Howard R, McShane R, Lindesay J, et al. Nursing home placement in the Donepezil and Memantine in Moderate to Severe Alzheimer's Disease (DOMINO-AD) trial: secondary and post-hoc analyses. Lancet Neurol 2015; 14:1171.</a></li><li><a class="nounderline abstract_t">Cummings JL. Use of cholinesterase inhibitors in clinical practice: evidence-based recommendations. Am J Geriatr Psychiatry 2003; 11:131.</a></li><li><a class="nounderline abstract_t">Clark CM, Karlawish JH. Alzheimer disease: current concepts and emerging diagnostic and therapeutic strategies. Ann Intern Med 2003; 138:400.</a></li><li><a class="nounderline abstract_t">Langa KM, Foster NL, Larson EB. Mixed dementia: emerging concepts and therapeutic implications. JAMA 2004; 292:2901.</a></li><li><a class="nounderline abstract_t">Grossberg GT, Desai AK. Management of Alzheimer's disease. J Gerontol A Biol Sci Med Sci 2003; 58:331.</a></li><li><a class="nounderline abstract_t">Feldman H, Gauthier S, Hecker J, et al. A 24-week, randomized, double-blind study of donepezil in moderate to severe Alzheimer's disease. Neurology 2001; 57:613.</a></li><li><a class="nounderline abstract_t">Tariot PN, Cummings JL, Katz IR, et al. A randomized, double-blind, placebo-controlled study of the efficacy and safety of donepezil in patients with Alzheimer's disease in the nursing home setting. J Am Geriatr Soc 2001; 49:1590.</a></li><li><a class="nounderline abstract_t">Winblad B, Kilander L, Eriksson S, et al. Donepezil in patients with severe Alzheimer's disease: double-blind, parallel-group, placebo-controlled study. Lancet 2006; 367:1057.</a></li><li><a class="nounderline abstract_t">Black SE, Doody R, Li H, et al. Donepezil preserves cognition and global function in patients with severe Alzheimer disease. Neurology 2007; 69:459.</a></li><li><a class="nounderline abstract_t">Burns A, Bernabei R, Bullock R, et al. Safety and efficacy of galantamine (Reminyl) in severe Alzheimer's disease (the SERAD study): a randomised, placebo-controlled, double-blind trial. Lancet Neurol 2009; 8:39.</a></li><li><a class="nounderline abstract_t">Qaseem A, Snow V, Cross JT Jr, et al. Current pharmacologic treatment of dementia: a clinical practice guideline from the American College of Physicians and the American Academy of Family Physicians. Ann Intern Med 2008; 148:370.</a></li><li><a class="nounderline abstract_t">Orrego F, Villanueva S. The chemical nature of the main central excitatory transmitter: a critical appraisal based upon release studies and synaptic vesicle localization. Neuroscience 1993; 56:539.</a></li><li><a class="nounderline abstract_t">Danysz W, Parsons CG. Glycine and N-methyl-D-aspartate receptors: physiological significance and possible therapeutic applications. Pharmacol Rev 1998; 50:597.</a></li><li><a class="nounderline abstract_t">Lancelot E, Beal MF. Glutamate toxicity in chronic neurodegenerative disease. Prog Brain Res 1998; 116:331.</a></li><li><a class="nounderline abstract_t">Kornhuber J, Weller M, Schoppmeyer K, Riederer P. Amantadine and memantine are NMDA receptor antagonists with neuroprotective properties. J Neural Transm Suppl 1994; 43:91.</a></li><li><a class="nounderline abstract_t">Reisberg B, Doody R, Stöffler A, et al. Memantine in moderate-to-severe Alzheimer's disease. N Engl J Med 2003; 348:1333.</a></li><li><a class="nounderline abstract_t">Reisberg B, Doody R, Stöffler A, et al. A 24-week open-label extension study of memantine in moderate to severe Alzheimer disease. Arch Neurol 2006; 63:49.</a></li><li><a class="nounderline abstract_t">Chen R, Chan PT, Chu H, et al. Treatment effects between monotherapy of donepezil versus combination with memantine for Alzheimer disease: A meta-analysis. PLoS One 2017; 12:e0183586.</a></li><li><a class="nounderline abstract_t">Tariot PN, Farlow MR, Grossberg GT, et al. Memantine treatment in patients with moderate to severe Alzheimer disease already receiving donepezil: a randomized controlled trial. JAMA 2004; 291:317.</a></li><li><a class="nounderline abstract_t">Porsteinsson AP, Grossberg GT, Mintzer J, et al. Memantine treatment in patients with mild to moderate Alzheimer's disease already receiving a cholinesterase inhibitor: a randomized, double-blind, placebo-controlled trial. Curr Alzheimer Res 2008; 5:83.</a></li><li><a class="nounderline abstract_t">McShane R, Areosa Sastre A, Minakaran N. Memantine for dementia. Cochrane Database Syst Rev 2006; :CD003154.</a></li><li><a class="nounderline abstract_t">Schneider LS, Dagerman KS, Higgins JP, McShane R. Lack of evidence for the efficacy of memantine in mild Alzheimer disease. Arch Neurol 2011; 68:991.</a></li><li><a class="nounderline abstract_t">Dysken MW, Sano M, Asthana S, et al. Effect of vitamin E and memantine on functional decline in Alzheimer disease: the TEAM-AD VA cooperative randomized trial. JAMA 2014; 311:33.</a></li><li><a class="nounderline abstract_t">Hanney M, Prasher V, Williams N, et al. Memantine for dementia in adults older than 40 years with Down's syndrome (MEADOWS): a randomised, double-blind, placebo-controlled trial. Lancet 2012; 379:528.</a></li><li><a class="nounderline abstract_t">Ridha BH, Josephs KA, Rossor MN. Delusions and hallucinations in dementia with Lewy bodies: worsening with memantine. Neurology 2005; 65:481.</a></li><li class="breakAll">FDA Grants Accelerated Approval for Alzheimer’s Drug. US Food and Drug Administration. Available at: https://www.fda.gov/news-events/press-announcements/fda-grants-accelerated-approval-alzheimers-drug (Accessed on June 07, 2021).</li><li><a class="nounderline abstract_t">Rabinovici GD. Controversy and Progress in Alzheimer's Disease - FDA Approval of Aducanumab. N Engl J Med 2021; 385:771.</a></li><li><a class="nounderline abstract_t">Alexander GC, Knopman DS, Emerson SS, et al. Revisiting FDA Approval of Aducanumab. N Engl J Med 2021; 385:769.</a></li><li><a class="nounderline abstract_t">Dunn B, Stein P, Temple R, Cavazzoni P. An Appropriate Use of Accelerated Approval - Aducanumab for Alzheimer's Disease. N Engl J Med 2021; 385:856.</a></li><li><a class="nounderline abstract_t">Knopman DS, Perlmutter JS. Prescribing Aducanumab in the Face of Meager Efficacy and Real Risks. Neurology 2021; 97:545.</a></li><li><a class="nounderline abstract_t">Alexander GC, Karlawish J. The Problem of Aducanumab for the Treatment of Alzheimer Disease. Ann Intern Med 2021; 174:1303.</a></li><li><a class="nounderline abstract_t">Moghavem N, Henderson VW, Greicius MD. Medicare Should Not Cover Aducanumab as a Treatment for Alzheimer's Disease. Ann Neurol 2021; 90:331.</a></li><li><a class="nounderline abstract_t">Hershey LA, Tarawneh R. Clinical Efficacy, Drug Safety, and Surrogate Endpoints: Has Aducanumab Met All of Its Expectations? Neurology 2021; 97:517.</a></li><li><a class="nounderline abstract_t">Salinas RA. Aducanumab for Alzheimer's disease: expediting approval and delaying science. BMJ Evid Based Med 2021; 26:214.</a></li><li><a class="nounderline abstract_t">Petersen RC. Aducanumab: What about the Patient? Ann Neurol 2021; 90:334.</a></li><li><a class="nounderline abstract_t">Cummings J, Salloway S. Aducanumab: Appropriate use recommendations. Alzheimers Dement 2022; 18:531.</a></li><li class="breakAll">Aduhelm (aducanumab-avwa injection). US FDA approved product information; Cambridge, MA: Biogen Inc; June 2021. (Available online at https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/761178s000lbl.pdf (Accessed June 07, 2021)).</li><li><a class="nounderline abstract_t">Sperling RA, Jack CR Jr, Black SE, et al. Amyloid-related imaging abnormalities in amyloid-modifying therapeutic trials: recommendations from the Alzheimer's Association Research Roundtable Workgroup. Alzheimers Dement 2011; 7:367.</a></li><li><a class="nounderline abstract_t">Alexander GC, Emerson S, Kesselheim AS. Evaluation of Aducanumab for Alzheimer Disease: Scientific Evidence and Regulatory Review Involving Efficacy, Safety, and Futility. JAMA 2021; 325:1717.</a></li><li><a class="nounderline abstract_t">McCleery J, Quinn TJ. Aducanumab and the certainty of evidence. Age Ageing 2021; 50:1899.</a></li><li><a class="nounderline abstract_t">Sevigny J, Chiao P, Bussière T, et al. The antibody aducanumab reduces Aβ plaques in Alzheimer's disease. Nature 2016; 537:50.</a></li><li class="breakAll">Center for Drug Evaluation and Research. Application number: 761178Orig1s000. Statistical review and evaluation. US Department of Health and Human Services, 2020.</li><li><a class="nounderline abstract_t">Schneider L. A resurrection of aducanumab for Alzheimer's disease. Lancet Neurol 2020; 19:111.</a></li><li class="breakAll">Combined FDA and Biogen briefing document. Peripheral and Central Nervous System (PCNS) Drugs Advisory Committee Meeting. November 6, 2020, Silver Spring, MD. Available at: https://www.fda.gov/media/143502/download (Accessed on September 07, 2021).</li><li><a class="nounderline abstract_t">Farina N, Llewellyn D, Isaac MG, Tabet N. Vitamin E for Alzheimer's dementia and mild cognitive impairment. Cochrane Database Syst Rev 2017; 1:CD002854.</a></li><li><a class="nounderline abstract_t">Sano M, Ernesto C, Thomas RG, et al. A controlled trial of selegiline, alpha-tocopherol, or both as treatment for Alzheimer's disease. The Alzheimer's Disease Cooperative Study. N Engl J Med 1997; 336:1216.</a></li><li><a class="nounderline abstract_t">Galasko DR, Peskind E, Clark CM, et al. Antioxidants for Alzheimer disease: a randomized clinical trial with cerebrospinal fluid biomarker measures. Arch Neurol 2012; 69:836.</a></li><li><a class="nounderline abstract_t">Miller ER 3rd, Pastor-Barriuso R, Dalal D, et al. Meta-analysis: high-dosage vitamin E supplementation may increase all-cause mortality. Ann Intern Med 2005; 142:37.</a></li><li><a class="nounderline abstract_t">Birks J, Flicker L. Selegiline for Alzheimer's disease. Cochrane Database Syst Rev 2000; :CD000442.</a></li><li><a class="nounderline abstract_t">Burke WJ, Roccaforte WH, Wengel SP, et al. L-deprenyl in the treatment of mild dementia of the Alzheimer type: results of a 15-month trial. J Am Geriatr Soc 1993; 41:1219.</a></li><li><a class="nounderline abstract_t">Potter LT. Discovery of treatments for Alzheimer's disease. Neurobiol Aging 1994; 15 Suppl 2:S67.</a></li><li><a class="nounderline abstract_t">Snyder HM, Corriveau RA, Craft S, et al. Vascular contributions to cognitive impairment and dementia including Alzheimer's disease. Alzheimers Dement 2015; 11:710.</a></li><li><a class="nounderline abstract_t">Deschaintre Y, Richard F, Leys D, Pasquier F. Treatment of vascular risk factors is associated with slower decline in Alzheimer disease. Neurology 2009; 73:674.</a></li><li><a class="nounderline abstract_t">Sabayan B, Westendorp RG. Blood pressure control and cognitive impairment--why low is not always better. JAMA Intern Med 2015; 175:586.</a></li><li><a class="nounderline abstract_t">Mossello E, Pieraccioli M, Nesti N, et al. Effects of low blood pressure in cognitively impaired elderly patients treated with antihypertensive drugs. JAMA Intern Med 2015; 175:578.</a></li><li><a class="nounderline abstract_t">Richard E, Gouw AA, Scheltens P, van Gool WA. Vascular care in patients with Alzheimer disease with cerebrovascular lesions slows progression of white matter lesions on MRI: the evaluation of vascular care in Alzheimer's disease (EVA) study. Stroke 2010; 41:554.</a></li><li><a class="nounderline abstract_t">Sparks DL, Sabbagh MN, Connor DJ, et al. Atorvastatin for the treatment of mild to moderate Alzheimer disease: preliminary results. Arch Neurol 2005; 62:753.</a></li><li><a class="nounderline abstract_t">Sano M, Bell KL, Galasko D, et al. A randomized, double-blind, placebo-controlled trial of simvastatin to treat Alzheimer disease. Neurology 2011; 77:556.</a></li><li><a class="nounderline abstract_t">Feldman HH, Doody RS, Kivipelto M, et al. Randomized controlled trial of atorvastatin in mild to moderate Alzheimer disease: LEADe. Neurology 2010; 74:956.</a></li><li><a class="nounderline abstract_t">Henderson VW. Estrogen, cognition, and a woman's risk of Alzheimer's disease. Am J Med 1997; 103:11S.</a></li><li><a class="nounderline abstract_t">Shumaker SA, Legault C, Rapp SR, et al. Estrogen plus progestin and the incidence of dementia and mild cognitive impairment in postmenopausal women: the Women's Health Initiative Memory Study: a randomized controlled trial. JAMA 2003; 289:2651.</a></li><li><a class="nounderline abstract_t">Shumaker SA, Legault C, Kuller L, et al. Conjugated equine estrogens and incidence of probable dementia and mild cognitive impairment in postmenopausal women: Women's Health Initiative Memory Study. JAMA 2004; 291:2947.</a></li><li><a class="nounderline abstract_t">Espeland MA, Rapp SR, Shumaker SA, et al. Conjugated equine estrogens and global cognitive function in postmenopausal women: Women's Health Initiative Memory Study. JAMA 2004; 291:2959.</a></li><li><a class="nounderline abstract_t">Yaffe K, Sawaya G, Lieberburg I, Grady D. Estrogen therapy in postmenopausal women: effects on cognitive function and dementia. JAMA 1998; 279:688.</a></li><li><a class="nounderline abstract_t">Wang PN, Liao SQ, Liu RS, et al. Effects of estrogen on cognition, mood, and cerebral blood flow in AD: a controlled study. Neurology 2000; 54:2061.</a></li><li><a class="nounderline abstract_t">Henderson VW, Paganini-Hill A, Miller BL, et al. Estrogen for Alzheimer's disease in women: randomized, double-blind, placebo-controlled trial. Neurology 2000; 54:295.</a></li><li><a class="nounderline abstract_t">Mulnard RA, Cotman CW, Kawas C, et al. Estrogen replacement therapy for treatment of mild to moderate Alzheimer disease: a randomized controlled trial. Alzheimer's Disease Cooperative Study. JAMA 2000; 283:1007.</a></li><li><a class="nounderline abstract_t">Asthana S, Baker LD, Craft S, et al. High-dose estradiol improves cognition for women with AD: results of a randomized study. Neurology 2001; 57:605.</a></li><li><a class="nounderline abstract_t">LeBlanc ES, Janowsky J, Chan BK, Nelson HD. Hormone replacement therapy and cognition: systematic review and meta-analysis. JAMA 2001; 285:1489.</a></li><li><a class="nounderline abstract_t">Rigaud AS, André G, Vellas B, et al. No additional benefit of HRT on response to rivastigmine in menopausal women with AD. Neurology 2003; 60:148.</a></li><li><a class="nounderline abstract_t">Rogers J, Webster S, Lue LF, et al. Inflammation and Alzheimer's disease pathogenesis. Neurobiol Aging 1996; 17:681.</a></li><li><a class="nounderline abstract_t">Cagnin A, Brooks DJ, Kennedy AM, et al. In-vivo measurement of activated microglia in dementia. Lancet 2001; 358:461.</a></li><li><a class="nounderline abstract_t">Andersen K, Launer LJ, Ott A, et al. Do nonsteroidal anti-inflammatory drugs decrease the risk for Alzheimer's disease? The Rotterdam Study. Neurology 1995; 45:1441.</a></li><li><a class="nounderline abstract_t">Firuzi O, Praticò D. Coxibs and Alzheimer's disease: should they stay or should they go? Ann Neurol 2006; 59:219.</a></li><li><a class="nounderline abstract_t">Rogers J, Kirby LC, Hempelman SR, et al. Clinical trial of indomethacin in Alzheimer's disease. Neurology 1993; 43:1609.</a></li><li><a class="nounderline abstract_t">Scharf S, Mander A, Ugoni A, et al. A double-blind, placebo-controlled trial of diclofenac/misoprostol in Alzheimer's disease. Neurology 1999; 53:197.</a></li><li><a class="nounderline abstract_t">Van Gool WA, Weinstein HC, Scheltens P, Walstra GJ. Effect of hydroxychloroquine on progression of dementia in early Alzheimer's disease: an 18-month randomised, double-blind, placebo-controlled study. Lancet 2001; 358:455.</a></li><li><a class="nounderline abstract_t">Aisen PS, Schafer KA, Grundman M, et al. Effects of rofecoxib or naproxen vs placebo on Alzheimer disease progression: a randomized controlled trial. JAMA 2003; 289:2819.</a></li><li><a class="nounderline abstract_t">Reines SA, Block GA, Morris JC, et al. Rofecoxib: no effect on Alzheimer's disease in a 1-year, randomized, blinded, controlled study. Neurology 2004; 62:66.</a></li><li><a class="nounderline abstract_t">AD2000 Collaborative Group, Bentham P, Gray R, et al. Aspirin in Alzheimer's disease (AD2000): a randomised open-label trial. Lancet Neurol 2008; 7:41.</a></li><li><a class="nounderline abstract_t">Jaturapatporn D, Isaac MG, McCleery J, Tabet N. Aspirin, steroidal and non-steroidal anti-inflammatory drugs for the treatment of Alzheimer's disease. Cochrane Database Syst Rev 2012; :CD006378.</a></li><li><a class="nounderline abstract_t">Birks J, Grimley Evans J. Ginkgo biloba for cognitive impairment and dementia. Cochrane Database Syst Rev 2009; :CD003120.</a></li><li><a class="nounderline abstract_t">Angell M, Kassirer JP. Alternative medicine--the risks of untested and unregulated remedies. N Engl J Med 1998; 339:839.</a></li><li><a class="nounderline abstract_t">Aisen PS, Schneider LS, Sano M, et al. High-dose B vitamin supplementation and cognitive decline in Alzheimer disease: a randomized controlled trial. JAMA 2008; 300:1774.</a></li><li><a class="nounderline abstract_t">Quinn JF, Raman R, Thomas RG, et al. Docosahexaenoic acid supplementation and cognitive decline in Alzheimer disease: a randomized trial. JAMA 2010; 304:1903.</a></li><li><a class="nounderline abstract_t">Freund-Levi Y, Eriksdotter-Jönhagen M, Cederholm T, et al. Omega-3 fatty acid treatment in 174 patients with mild to moderate Alzheimer disease: OmegAD study: a randomized double-blind trial. Arch Neurol 2006; 63:1402.</a></li></ol></div><div id="topicVersionRevision">Topic 5073 Version 41.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12517232" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Efficacy of cholinesterase inhibitors in the treatment of neuropsychiatric symptoms and functional impairment in Alzheimer disease: a meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18316756" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Effectiveness of cholinesterase inhibitors and memantine for treating dementia: evidence review for a clinical practice guideline.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11342679" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Practice parameter: management of dementia (an evidence-based review). Report of the Quality Standards Subcommittee of the American Academy of Neurology.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16081444" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Cholinesterase inhibitors for patients with Alzheimer's disease: systematic review of randomised clinical trials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25858345" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Rivastigmine for Alzheimer's disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16437532" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Cholinesterase inhibitors for Alzheimer's disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16437430" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Donepezil for dementia due to Alzheimer's disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23862185" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Galantamine for vascular cognitive impairment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12975222" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Efficacy and safety of cholinesterase inhibitors in Alzheimer's disease: a meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15220031" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Long-term donepezil treatment in 565 patients with Alzheimer's disease (AD2000): randomised double-blind trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15220027" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : AD2000: donepezil in Alzheimer's disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11861686" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Cholinesterase inhibitor treatment alters the natural history of Alzheimer's disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22397651" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Donepezil and memantine for moderate-to-severe Alzheimer's disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26515660" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Nursing home placement in the Donepezil and Memantine in Moderate to Severe Alzheimer's Disease (DOMINO-AD) trial: secondary and post-hoc analyses.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12611743" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Use of cholinesterase inhibitors in clinical practice: evidence-based recommendations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12614093" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Alzheimer disease: current concepts and emerging diagnostic and therapeutic strategies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15598922" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Mixed dementia: emerging concepts and therapeutic implications.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12663697" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Management of Alzheimer's disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11524468" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : A 24-week, randomized, double-blind study of donepezil in moderate to severe Alzheimer's disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11843990" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : A randomized, double-blind, placebo-controlled study of the efficacy and safety of donepezil in patients with Alzheimer's disease in the nursing home setting.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16581404" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Donepezil in patients with severe Alzheimer's disease: double-blind, parallel-group, placebo-controlled study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17664405" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Donepezil preserves cognition and global function in patients with severe Alzheimer disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19042161" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Safety and efficacy of galantamine (Reminyl) in severe Alzheimer's disease (the SERAD study): a randomised, placebo-controlled, double-blind trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18316755" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Current pharmacologic treatment of dementia: a clinical practice guideline from the American College of Physicians and the American Academy of Family Physicians.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7902967" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : The chemical nature of the main central excitatory transmitter: a critical appraisal based upon release studies and synaptic vesicle localization.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9860805" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Glycine and N-methyl-D-aspartate receptors: physiological significance and possible therapeutic applications.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9932386" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Glutamate toxicity in chronic neurodegenerative disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7884411" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Amantadine and memantine are NMDA receptor antagonists with neuroprotective properties.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12672860" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Memantine in moderate-to-severe Alzheimer's disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16401736" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : A 24-week open-label extension study of memantine in moderate to severe Alzheimer disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28827830" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Treatment effects between monotherapy of donepezil versus combination with memantine for Alzheimer disease: A meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14734594" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Memantine treatment in patients with moderate to severe Alzheimer disease already receiving donepezil: a randomized controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18288936" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Memantine treatment in patients with mild to moderate Alzheimer's disease already receiving a cholinesterase inhibitor: a randomized, double-blind, placebo-controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16625572" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Memantine for dementia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21482915" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Lack of evidence for the efficacy of memantine in mild Alzheimer disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24381967" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Effect of vitamin E and memantine on functional decline in Alzheimer disease: the TEAM-AD VA cooperative randomized trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22236802" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Memantine for dementia in adults older than 40 years with Down's syndrome (MEADOWS): a randomised, double-blind, placebo-controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16087923" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Delusions and hallucinations in dementia with Lewy bodies: worsening with memantine.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16087923" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Delusions and hallucinations in dementia with Lewy bodies: worsening with memantine.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34320284" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Controversy and Progress in Alzheimer's Disease - FDA Approval of Aducanumab.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34320282" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Revisiting FDA Approval of Aducanumab.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34320283" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : An Appropriate Use of Accelerated Approval - Aducanumab for Alzheimer's Disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34233938" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Prescribing Aducanumab in the Face of Meager Efficacy and Real Risks.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34138642" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : The Problem of Aducanumab for the Treatment of Alzheimer Disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34278596" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Medicare Should Not Cover Aducanumab as a Treatment for Alzheimer's Disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34233940" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Clinical Efficacy, Drug Safety, and Surrogate Endpoints: Has Aducanumab Met All of Its Expectations?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34261765" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Aducanumab for Alzheimer's disease: expediting approval and delaying science.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34322904" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Aducanumab: What about the Patient?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34314093" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Aducanumab: Appropriate use recommendations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34314093" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Aducanumab: Appropriate use recommendations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21784348" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Amyloid-related imaging abnormalities in amyloid-modifying therapeutic trials: recommendations from the Alzheimer's Association Research Roundtable Workgroup.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33783469" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Evaluation of Aducanumab for Alzheimer Disease: Scientific Evidence and Regulatory Review Involving Efficacy, Safety, and Futility.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34405228" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Aducanumab and the certainty of evidence.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27582220" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : The antibody aducanumab reduces Aβplaques in Alzheimer's disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27582220" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : The antibody aducanumab reduces Aβplaques in Alzheimer's disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31978357" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : A resurrection of aducanumab for Alzheimer's disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31978357" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : A resurrection of aducanumab for Alzheimer's disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28128435" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Vitamin E for Alzheimer's dementia and mild cognitive impairment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9110909" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : A controlled trial of selegiline, alpha-tocopherol, or both as treatment for Alzheimer's disease. The Alzheimer's Disease Cooperative Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22431837" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Antioxidants for Alzheimer disease: a randomized clinical trial with cerebrospinal fluid biomarker measures.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15537682" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Meta-analysis: high-dosage vitamin E supplementation may increase all-cause mortality.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10796544" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Selegiline for Alzheimer's disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8227897" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : L-deprenyl in the treatment of mild dementia of the Alzheimer type: results of a 15-month trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7700465" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Discovery of treatments for Alzheimer's disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25510382" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Vascular contributions to cognitive impairment and dementia including Alzheimer's disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19720973" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Treatment of vascular risk factors is associated with slower decline in Alzheimer disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25730401" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Blood pressure control and cognitive impairment--why low is not always better.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25730775" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : Effects of low blood pressure in cognitively impaired elderly patients treated with antihypertensive drugs.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20056923" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : Vascular care in patients with Alzheimer disease with cerebrovascular lesions slows progression of white matter lesions on MRI: the evaluation of vascular care in Alzheimer's disease (EVA) study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15883262" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : Atorvastatin for the treatment of mild to moderate Alzheimer disease: preliminary results.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21795660" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : A randomized, double-blind, placebo-controlled trial of simvastatin to treat Alzheimer disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20200346" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : Randomized controlled trial of atorvastatin in mild to moderate Alzheimer disease: LEADe.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9344402" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : Estrogen, cognition, and a woman's risk of Alzheimer's disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12771112" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : Estrogen plus progestin and the incidence of dementia and mild cognitive impairment in postmenopausal women: the Women's Health Initiative Memory Study: a randomized controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15213206" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : Conjugated equine estrogens and incidence of probable dementia and mild cognitive impairment in postmenopausal women: Women's Health Initiative Memory Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15213207" id="rid75" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>76 : Conjugated equine estrogens and global cognitive function in postmenopausal women: Women's Health Initiative Memory Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9496988" id="rid76" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>77 : Estrogen therapy in postmenopausal women: effects on cognitive function and dementia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10851363" id="rid77" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>78 : Effects of estrogen on cognition, mood, and cerebral blood flow in AD: a controlled study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10668686" id="rid78" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>79 : Estrogen for Alzheimer's disease in women: randomized, double-blind, placebo-controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10697060" id="rid79" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>80 : Estrogen replacement therapy for treatment of mild to moderate Alzheimer disease: a randomized controlled trial. Alzheimer's Disease Cooperative Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11524467" id="rid80" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>81 : High-dose estradiol improves cognition for women with AD: results of a randomized study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11255426" id="rid81" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>82 : Hormone replacement therapy and cognition: systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12525745" id="rid82" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>83 : No additional benefit of HRT on response to rivastigmine in menopausal women with AD.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8892340" id="rid83" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>84 : Inflammation and Alzheimer's disease pathogenesis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11513911" id="rid84" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>85 : In-vivo measurement of activated microglia in dementia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7644037" id="rid85" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>86 : Do nonsteroidal anti-inflammatory drugs decrease the risk for Alzheimer's disease? The Rotterdam Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16402383" id="rid86" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>87 : Coxibs and Alzheimer's disease: should they stay or should they go?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8351023" id="rid87" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>88 : Clinical trial of indomethacin in Alzheimer's disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10408559" id="rid88" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>89 : A double-blind, placebo-controlled trial of diclofenac/misoprostol in Alzheimer's disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11513909" id="rid89" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>90 : Effect of hydroxychloroquine on progression of dementia in early Alzheimer's disease: an 18-month randomised, double-blind, placebo-controlled study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12783912" id="rid90" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>91 : Effects of rofecoxib or naproxen vs placebo on Alzheimer disease progression: a randomized controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14718699" id="rid91" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>92 : Rofecoxib: no effect on Alzheimer's disease in a 1-year, randomized, blinded, controlled study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18068522" id="rid92" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>93 : Aspirin in Alzheimer's disease (AD2000): a randomised open-label trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22336816" id="rid93" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>94 : Aspirin, steroidal and non-steroidal anti-inflammatory drugs for the treatment of Alzheimer's disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19160216" id="rid94" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>95 : Ginkgo biloba for cognitive impairment and dementia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9738094" id="rid95" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>96 : Alternative medicine--the risks of untested and unregulated remedies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18854539" id="rid96" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>97 : High-dose B vitamin supplementation and cognitive decline in Alzheimer disease: a randomized controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21045096" id="rid97" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>98 : Docosahexaenoic acid supplementation and cognitive decline in Alzheimer disease: a randomized trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17030655" id="rid98" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>99 : Omega-3 fatty acid treatment in 174 patients with mild to moderate Alzheimer disease: OmegAD study: a randomized double-blind trial.</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
